NEW YORK (GenomeWeb News) — Gene Logic and Genstruct will partner in an effort to market screening technologies that their pharmaceutical clients could use to test the potential toxicity of various compounds, the firms said today in a joint statement.
Under the collaboration, Gene Logic will offer its toxicology databases and data on specific compounds for preclinical and clinical research to pharmaceutical, biotechnology, consumer products and other industries, the company said. Genstruct will apply its Causal Network Modeling platform to create network models that capture toxicity potential of compounds.
The companies also will conduct co-marketing initiatives for each others' products. They also said that they intend to collaborate on personalized oncology therapy.
Genstruct President and CEO Keith Elliston, who formerly served as CSO of Gene Logic, said in a statement that the partners plan to generate gene expression data from patient tumors, which will be analyzed using Genstruct's systems biology platform. The information derived from the analysis could be used by physicians to devise optimal therapy for each patient, he said.